Barinthus Biotherapeutics (BRNS) Receivables - Other (2020 - 2025)
Barinthus Biotherapeutics' Receivables - Other history spans 6 years, with the latest figure at $1.1 million for Q4 2025.
- For Q4 2025, Receivables - Other fell 84.48% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 84.48%, while the annual FY2025 figure was $1.1 million, 84.48% down from the prior year.
- Receivables - Other reached $1.1 million in Q4 2025 per BRNS's latest filing, down from $4.6 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $15.0 million in Q3 2024 to a low of $143000.0 in Q2 2022.
- Average Receivables - Other over 5 years is $4.5 million, with a median of $4.5 million recorded in 2022.
- Peak YoY movement for Receivables - Other: plummeted 96.86% in 2022, then soared 1195.99% in 2024.
- A 5-year view of Receivables - Other shows it stood at $6.2 million in 2021, then dropped by 27.1% to $4.5 million in 2022, then increased by 8.08% to $4.9 million in 2023, then soared by 45.46% to $7.1 million in 2024, then plummeted by 84.48% to $1.1 million in 2025.
- Per Business Quant, the three most recent readings for BRNS's Receivables - Other are $1.1 million (Q4 2025), $4.6 million (Q3 2025), and $4.5 million (Q2 2025).